Literature DB >> 32737792

Comparative study of AQP4 antibody-related diseases and MOG antibody-related diseases among the population in Hunan, China.

Xiqian Chen1, Yijun Ren1, Yiliu Zhang1, Wei Lu2.   

Abstract

To compare the clinical, imaging, and prognostic characteristics of AQP4 antibody-related diseases and MOG antibody-related diseases. The clinical data of 56 AQP4 antibody-positive patients and 14 MOG antibody-positive patients in the Second Xiangya Hospital of Central South University from June 2016 to June 2019 were collected. 92.9% of the patients with positive AQP4 antibody were females and 64.3% of patients with positive MOG antibody were females (P = 0.004). Patients with positive AQP4 antibody were more likely to have limb movement (P < 0.001) or limb sensory dysfunction (P < 0.001), and were more likely to have limb twitching (P = 0.036). In addition, AQP4 antibody-positive patients were more likely to have positive ANA (P = 0.013) and SSA antibody (P = 0.029), Ro-52 antibody (P = 0.047), immunoglobulin (P = 0.007), thyroid antibody (P = 0.007), abnormal C3 (P = 0.011), abnormal C4 (P = 0.014) than MOG antibody-positive patients. The involvement rate of head in MOG antibody-positive patients was higher than AQP4 antibody-positive patients (P = 0.029). The severity of clinical symptoms in AQP4-positive patients was usually more serious than that in MOG-positive patients (P < 0.001). The residual neurological deficit after treatment in AQP4-positive group was usually more serious than that in MOG-positive group (P < 0.001). AQP4 antibody-positive patients had a higher prevalence in women than MOG antibody-positive patients, and AQP4 antibody-positive patients were more likely to have spinal cord involvement symptoms and connective tissue antibody abnormalities. The EDSS score of them were higher than that of MOG antibody-positive patients after treatment, and the prognosis was worse.
© 2020. Belgian Neurological Society.

Entities:  

Keywords:  AQP4 antibody; Clinical features; Comparative; Epidemiological characteristics; MOG antibody; Prognosis; Treatment

Mesh:

Substances:

Year:  2020        PMID: 32737792     DOI: 10.1007/s13760-020-01455-7

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  26 in total

Review 1.  Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations.

Authors:  Maciej Juryńczyk; Anu Jacob; Kazuo Fujihara; Jacqueline Palace
Journal:  Pract Neurol       Date:  2018-12-08

Review 2.  T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  A Iglesias; J Bauer; T Litzenburger; A Schubart; C Linington
Journal:  Glia       Date:  2001-11       Impact factor: 7.452

Review 3.  The spectrum of MOG autoantibody-associated demyelinating diseases.

Authors:  Markus Reindl; Franziska Di Pauli; Kevin Rostásy; Thomas Berger
Journal:  Nat Rev Neurol       Date:  2013-06-25       Impact factor: 42.937

4.  Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica.

Authors:  John Soltys; Yiting Liu; Alanna Ritchie; Scott Wemlinger; Kristin Schaller; Hannah Schumann; Gregory P Owens; Jeffrey L Bennett
Journal:  J Clin Invest       Date:  2019-04-08       Impact factor: 14.808

5.  Anti-aquaporin-4 antibody-positive optic neuritis treated with double-filtration plasmapheresis.

Authors:  Hideyuki Yoshida; Akira Ando; Kenichiro Sho; Masako Akioka; Emi Kawai; Eiko Arai; Tetsuya Nishimura; Akiyo Shinde; Hiroya Masaki; Kanji Takahashi; Mineo Takagi; Keiko Tanaka
Journal:  J Ocul Pharmacol Ther       Date:  2010-08       Impact factor: 2.671

6.  Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls.

Authors:  B G Xiao; C Linington; H Link
Journal:  J Neuroimmunol       Date:  1991-02       Impact factor: 3.478

Review 7.  Myelin oligodendrocyte glycoprotein antibodies in neurological disease.

Authors:  Markus Reindl; Patrick Waters
Journal:  Nat Rev Neurol       Date:  2019-02       Impact factor: 42.937

Review 8.  Defining distinct features of anti-MOG antibody associated central nervous system demyelination.

Authors:  Martin S Weber; Tobias Derfuss; Imke Metz; Wolfgang Brück
Journal:  Ther Adv Neurol Disord       Date:  2018-03-29       Impact factor: 6.570

Review 9.  Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes.

Authors:  Marco A Lana-Peixoto; Natália Talim
Journal:  Biomedicines       Date:  2019-06-12

Review 10.  Epidemiology of neuromyelitis optica spectrum disorder in Denmark (1998-2008, 2007-2014).

Authors:  Nasrin Asgari; Soeren T Lillevang; Hanne P B Skejoe; Kirsten O Kyvik
Journal:  Brain Behav       Date:  2019-06-11       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.